We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Celerion Recognized as Member of the UK Respiratory Therapeutic Capability Cluster
News

Celerion Recognized as Member of the UK Respiratory Therapeutic Capability Cluster

Celerion Recognized as Member of the UK Respiratory Therapeutic Capability Cluster
News

Celerion Recognized as Member of the UK Respiratory Therapeutic Capability Cluster

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Celerion Recognized as Member of the UK Respiratory Therapeutic Capability Cluster"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

 The UK Respiratory Therapeutic Capability Cluster is a unique cooperative of internationally leading clinicians and scientists whose aim is to improve the speed of developing innovative therapies for respiratory diseases by working in collaboration with research groups of the pharmaceutical industry.

The collaboration with the UK Respiratory Therapeutic Capability Cluster provides access to patients suffering from asthma, COPD, cystic fibrosis, bronchiectasis and interstitial lung disease. Celerion has access to laboratory capabilities (flow cytometry, flow cytometric cell sorting, microbiology, 16S, deep sequencing, MLST, transcriptomics) as well as lung imaging techniques (CT acquisition of images, dedicated MRI time, advanced CT analysis capabilities and MRI acquisition of images).

“The membership of Celerion into the UK Respiratory Therapeutic Capability Cluster will provide our clients a one stop solution that provides access to targeted patient populations. Celerion provides a full service approach for clinical studies from protocol development through to final report,” said Phil Bach, Vice President of Clinical Research at Celerion. “We have seen an increasing demand for conducting Phase I studies in patients with access to more specialized techniques. This collaboration allows Celerion to address this need and assist clients to gain insight to data earlier in drug development programs.”

All the centres in the UK Respiratory Therapeutic Capability Cluster are recognised for their excellence in basic and translational research in respiratory medicine. Celerion is delighted to be part of this distinguished team of talented individuals, with a proven track-record in helping industry better to understand airways disease and facilitate drug discovery.

Advertisement